Peptide RX

back to claim graph

proof receipt / export

Research pack / PRX-GHSR-002

Public-safe research pack receipt surface. Raw sequence remains outside the claim graph.

grade D status export surface receipt 140e02f9e411 proof 100%

what this node claims

Research pack / PRX-GHSR-002

Public-safe research pack receipt surface. Raw sequence remains outside the claim graph.

Open source surface Research pack

vertical proof spine

  1. 01 GHSR1a target / grade B / 70% 1 debt
  2. 02 GHSR WT fold / grade B / 74% 1 debt
  3. 03 AlphaFold metrics / GHSR alphafold metric / grade B / 74% 1 debt
  4. 04 PRX-GHSR-002 candidate / grade D / 36% 3 debt
  5. 05 Initial digest — GHSR1a finding / grade C / 47% 1 debt
  6. 06 Research pack / PRX-GHSR-002 export / grade D / 10% 3 debt

evidence / risk instrument

74%
usable with debt
structure evidence gates risk export lineage 74
low debt pressure 32%
82%structurestrong
pLDDT 81.6
55%evidencethin
grade C
60%gatesusable
3/5 gates
100%riskstrong
0 hard flags
92%exportstrong
surface linked
100%lineagestrong
complete spine

proof completeness

100% complete spine
  1. 01 target
  2. 02 fold
  3. 03 alphafold metric
  4. 04 candidate
  5. 05 finding
  6. 06 export

Metrics and receipt inputs

evidence grade
D
excludes public graph
  • raw sequence
  • protocol instructions
formats
  • html
  • json
  • markdown
gate passed
3
includes
  • target context
  • AlphaFold confidence context
  • candidate gates
  • evidence limits
  • proof receipt
pda envelope
true
sequence redacted
true

AlphaFold metrics visual

Confident backbone model

81.6

366 residues / min 27.77 / max 98.75 / source alphafold db

PAE matrix for linked target
Very high 50.8% 186 residues / >=90
Confident 27.3% 100 residues / 70-89
Low 11.5% 42 residues / 50-69
Very low 10.4% 38 residues / <50

usable fold context with explicit model-confidence limits

Near-complete coverage / observed 366 of 366 residues.

  • residues 1-36 / mean 35.02
  • residues 341-366 / mean 56.57
  • residues 284-294 / mean 65.33
  • residues 246-251 / mean 60.33
proof debt register

Visible limits, not hidden cleanup.

32%

Peptide RX keeps unresolved proof debt attached to the public receipt. Some debts should be resolved; redaction and research-use boundaries should stay visible.

low not clinical validation keep the research-use boundary visible; do not promote as clinical
low research-use export only keep the research-use boundary visible; do not promote as clinical
low sequence redacted keep sequence redacted publicly; expose only through authorized records
low computational-only status add independent evidence, challenge result, or witness review before strengthening
high low evidence grade attach graded finding with source-linked evidence
low sequence redacted keep sequence redacted publicly; expose only through authorized records

weakness and challenge edges

What would stop this from becoming stronger.

debt severity export claim strength next proof needed
not clinical validation low visible watch keep the research-use boundary visible; do not promote as clinical
research-use export only low visible watch keep the research-use boundary visible; do not promote as clinical
sequence redacted low visible watch keep sequence redacted publicly; expose only through authorized records
computational-only status low visible watch add independent evidence, challenge result, or witness review before strengthening
low evidence grade high blocks weakens attach graded finding with source-linked evidence
sequence redacted low visible watch keep sequence redacted publicly; expose only through authorized records

what supports it

candidate has public research-pack surface candidate:PRX-GHSR-002 -> export:candidate:PRX-GHSR-002 exports / D / 0.72

what it supports

No downstream proof edge yet.

Research-use boundary

This receipt describes public computational research state. It does not expose raw candidate sequences and does not make a clinical claim.